Is an oral selective estrogen receptor degrader (SERD) more effective than an aromatase inhibitor (AI) as first‑line endocrine therapy for hormone receptor‑positive, HER2‑positive metastatic breast cancer?

Is an Oral SERD More Efficient Than an AI as First-Line Endocrine Therapy for HR+HER2- Metastatic Breast Cancer?

B - FALSE

Aromatase inhibitors (AIs) remain the preferred first-line endocrine therapy for postmenopausal women with HR+HER2- metastatic breast cancer, not oral SERDs. Current guidelines consistently recommend AIs as the standard initial approach, with oral SERDs reserved for later lines of therapy, particularly in patients with ESR1 mutations after disease progression 1.

Guideline-Based First-Line Recommendations

The most recent ASCO guidelines (2016, updated 2021) explicitly state that for postmenopausal women, aromatase inhibitors are the preferred first-line endocrine therapy 1. The 2020 NCCN guidelines similarly designate AIs (anastrozole, letrozole, exemestane) as Category 1 preferred regimens for first-line treatment 2.

The evidence hierarchy is clear:

• First-line: AI ± CDK4/6 inhibitor (Category 1)
• Second-line: Fulvestrant 500mg (the only approved SERD until recently) ± CDK4/6 inhibitor or exemestane + everolimus 1

Why AIs Are Preferred First-Line

Multiple randomized trials have demonstrated that AIs consistently show superior results to tamoxifen as first-line therapy in terms of response rate, time to progression, and in some cases overall survival 3. The ATAC trial with 100 months follow-up showed anastrozole superiority over tamoxifen (HR for DFS 0.85; 95% CI 0.76-0.94; P=0.003) 4.

Importantly, ESR1 mutations—the primary target where oral SERDs show advantage—are uncommon in treatment-naïve metastatic disease 5. These mutations typically emerge as an acquired resistance mechanism after AI exposure, occurring in up to 40% of patients progressing on first-line AI therapy 6, 7, 8.

The Role of Oral SERDs: Post-Progression, Not First-Line

Recent meta-analyses of oral SERDs demonstrate their benefit is concentrated in ESR1-mutated tumors (PFS HR 0.57; 95% CI 0.48-0.67), with no significant PFS advantage in ESR1 wild-type disease 6. Another meta-analysis confirmed this pattern: overall PFS did not differ significantly (HR 0.80; 95% CI 0.62-1.04; p=0.09), but ESR1-mutated subgroups showed clear benefit (HR 0.57; 95% CI 0.45-0.73; p<0.01) 7.

The clinical positioning is therefore:

• Oral SERDs excel after CDK4/6i + AI progression, particularly with ESR1 mutations 6, 7, 8, 9
• They represent a paradigm shift for second-line therapy, not first-line 7, 9
• Elacestrant is FDA-approved specifically for ESR1-mutated disease after progression 10, 8

First-Line Combination Strategies

When considering first-line combinations, guidelines support:

• AI + CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) as preferred 1, 2
• Fulvestrant + AI may be offered for select patients without prior adjuvant endocrine therapy 1, 2
• Fulvestrant + CDK4/6 inhibitor is an alternative first-line option 2

Notably, oral SERDs are being evaluated in first-line combinations with CDK4/6 inhibitors in ongoing trials 9, 11, but these remain investigational and are not yet standard of care.

Clinical Algorithm for First-Line Selection

For postmenopausal women with HR+HER2- metastatic breast cancer:

1. Standard approach: AI (anastrozole, letrozole, or exemestane) + CDK4/6 inhibitor
2. Alternative if CDK4/6i contraindicated: AI monotherapy or fulvestrant 500mg
3. If prior adjuvant AI discontinued >12 months ago: May restart same AI class
4. If prior adjuvant AI discontinued ≤12 months ago: Switch to different endocrine agent (fulvestrant preferred)

For premenopausal women: Ovarian suppression/ablation + AI (or tamoxifen) ± CDK4/6 inhibitor 1.

Common Pitfalls to Avoid

• Do not use oral SERDs first-line outside clinical trials—the evidence supports their use after AI progression, not as initial therapy
• Do not assume all endocrine therapies are interchangeable—mechanism of action and resistance patterns differ significantly
• Do not skip ESR1 mutation testing after AI progression if considering oral SERD therapy, as this is where benefit is concentrated 5, 6
• Do not combine chemotherapy with endocrine therapy outside clinical trials—sequential therapy is preferred 3, 1

The evidence is unequivocal: AIs remain the gold standard for first-line endocrine therapy in HR+HER2- metastatic breast cancer, with oral SERDs emerging as important second-line options, particularly for ESR1-mutated disease.